Philippe Hernigou1, Jean Charles Auregan2, Arnaud Dubory3, Charles Henri Flouzat Lachaniette3, Hélène Rouard4. 1. Orthopedic Department, Henri Mondor Hospital, University Paris East, Paris, France. philippe.hernigou@wanadoo.fr. 2. Orthopedic Department, Antoine Beclère Hospital, University Paris West, Paris, France. 3. Orthopedic Department, Henri Mondor Hospital, University Paris East, Paris, France. 4. Etablissement Français du Sang, Henri Mondor Hospital, University Paris East, Paris, France.
Abstract
PURPOSE:Corticoid treatment associated with haematologic treatments can lead to ankle osteonecrosis in children's survivors of acute leukemia (ALL). Based on the efficiency of mesenchymal stem cells (MSCs) in hip osteonecrosis, we performed an evaluation of this treatment in 51 children and adolescents who had symptomatic ankle osteonecrosis after therapy for haematologic cancer. MATERIAL AND METHODS: The 51 patients had a total of 79 osteonecrosis sites on MRI, with 29 talus sites, 18 metaphyseal tibia sites, 12 epiphyseal tibia sites, eight calcaneus sites, six fibula sites, four navicular sites, and two cuboid sites. In this prospective randomized trial, 37 ankles were addressed for cell therapy, 37 others for core decompression alone, and 20 were considered as a control group without treatment. We analyzed the outcome of this treatment osteonecrosis, the number and characteristics of bone marrow mesenchymal cells (MSCs) that could be transplanted, and the risks of tumorigenesis in these patients with haematologic cancers. The patients were operated on over a period of ten years from 2000 to 2010 and were monitored through December 31, 2019. RESULTS: Despite a normal systemic blood cells count, MSCs in the iliac crest (counted as CFU-F) were in low number (1021 MSCs/mL; range 314-3015) and were of host origin after even allogeneic bone marrow transplantation. Better clinical outcomes (pain, foot and ankle deformity) and osteonecrosis repair on MRI with absence of collapse were obtained in ankles that received cell therapy as compared with those with core decompression alone or those without initial surgery. No tumour was found on MRI at the sites of injection and this study found no increased risk of recurrence or of new cancer in this population after an average follow-up of 15 years. CONCLUSIONS: These results suggest that autologous MSCs can improve the quality of life of leukemia survivors with ankle osteonecrosis.
RCT Entities:
PURPOSE: Corticoid treatment associated with haematologic treatments can lead to ankle osteonecrosis in children's survivors of acute leukemia (ALL). Based on the efficiency of mesenchymal stem cells (MSCs) in hip osteonecrosis, we performed an evaluation of this treatment in 51 children and adolescents who had symptomatic ankle osteonecrosis after therapy for haematologic cancer. MATERIAL AND METHODS: The 51 patients had a total of 79 osteonecrosis sites on MRI, with 29 talus sites, 18 metaphyseal tibia sites, 12 epiphyseal tibia sites, eight calcaneus sites, six fibula sites, four navicular sites, and two cuboid sites. In this prospective randomized trial, 37 ankles were addressed for cell therapy, 37 others for core decompression alone, and 20 were considered as a control group without treatment. We analyzed the outcome of this treatment osteonecrosis, the number and characteristics of bone marrow mesenchymal cells (MSCs) that could be transplanted, and the risks of tumorigenesis in these patients with haematologic cancers. The patients were operated on over a period of ten years from 2000 to 2010 and were monitored through December 31, 2019. RESULTS: Despite a normal systemic blood cells count, MSCs in the iliac crest (counted as CFU-F) were in low number (1021 MSCs/mL; range 314-3015) and were of host origin after even allogeneic bone marrow transplantation. Better clinical outcomes (pain, foot and ankle deformity) and osteonecrosis repair on MRI with absence of collapse were obtained in ankles that received cell therapy as compared with those with core decompression alone or those without initial surgery. No tumour was found on MRI at the sites of injection and this study found no increased risk of recurrence or of new cancer in this population after an average follow-up of 15 years. CONCLUSIONS: These results suggest that autologous MSCs can improve the quality of life of leukemia survivors with ankle osteonecrosis.
Entities:
Keywords:
Ankle osteonecrosis; Children cancer; Children osteonecrosis; Corticosteroid osteonecrosis; Distal tibia osteonecrosis; Leukemia survivors; Mesenchymal stem cells; Talus osteonecrosis
Authors: Philippe Hernigou; Arnaud Dubory; Charles Henri Flouzat Lachaniette; Issam Khaled; Nathalie Chevallier; Helene Rouard Journal: Int Orthop Date: 2018-01-05 Impact factor: 3.075
Authors: Stephanie B Dixon; Yan Chen; Yutaka Yasui; Ching-Hon Pui; Stephen P Hunger; Lewis B Silverman; Kirsten K Ness; Daniel M Green; Rebecca M Howell; Wendy M Leisenring; Nina S Kadan-Lottick; Kevin R Krull; Kevin C Oeffinger; Joseph P Neglia; Ann C Mertens; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Paul C Nathan Journal: J Clin Oncol Date: 2020-07-24 Impact factor: 44.544
Authors: Philippe Hernigou; Charles Henri Flouzat Lachaniette; Jerome Delambre; Nathalie Chevallier; Helene Rouard Journal: Int Orthop Date: 2014-06-07 Impact factor: 3.075
Authors: Charles-Henri Flouzat-Lachaniette; François Roubineau; Clemence Heyberger; Charlie Bouthors; Philippe Hernigou Journal: Int Orthop Date: 2015-12-03 Impact factor: 3.075
Authors: Philippe Hernigou; Charles Henri Flouzat-Lachaniette; Gildasio Daltro; Frederic Galacteros Journal: J Bone Joint Surg Am Date: 2016-07-06 Impact factor: 5.284
Authors: Rajen Mody; Suwen Li; Douglas C Dover; Stephen Sallan; Wendy Leisenring; Kevin C Oeffinger; Yutaka Yasui; Leslie L Robison; Joseph P Neglia Journal: Blood Date: 2008-03-11 Impact factor: 25.476